Literature DB >> 73462

Inhibition of antibody production in plasmacytoma cells by antigen.

A K Abbas, G G Klaus.   

Abstract

Tissue culture-adapted MOPC 315 mouse plasmacytoma cells which secrete monoclonal anti-DNP IgA antibody, were cultured with a variety of DNP-carrier conjugates and the production of IgA measured by pulse labeling with [3H]leucine and by plaque-forming cell assays. DNP-coupled bovine, human and rabbit gamma-globulins (containing 9 to 12 DNP groups per 50 000 mol wt of carrier) inhibited the synthesis and secretion of IgA by 40 to 80%. This inhibition was specific, since unconjugated globulins were ineffective, non-IgA proteins and DNA synthesis remained unaffected, and DNP-globulins had no effect on X5563 cells which do not bind DNP. The degree of suppression of antibody production dependen on the concentration and epitone density of the antigen and on the duration of exposure of cells to it, and was no attributable to absorption of secreted antibody by cell-bound antigen. Comparably substituted DNP conjugates of F(ab')2 and intact globulins were equally inhibitory. The inhibition of antibody synthesis by DNP-BGG was reversible following removal of the antigen. This phenomenon is similar in many respects to the antigen-induced blockade of normal antibody-secreting cells, and provides a valuable model system for analyzing the mechanisms of antigen-mediated cellular inactivation.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 73462     DOI: 10.1002/eji.1830071003

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  12 in total

1.  Soluble and immobilized anti-Ig antibodies in the regulation of LPS-induced lymphoblasts.

Authors:  D B Symons; C A Clarkson; F J Hall
Journal:  Immunology       Date:  1985-01       Impact factor: 7.397

2.  Suppression with anti-Ig of immunoglobulin secretion by pig lymphoblasts.

Authors:  D B Symons; C A Clarkson
Journal:  Immunology       Date:  1983-07       Impact factor: 7.397

3.  In vitro synthesis of IgE by human peripheral blood leucocytes. III. Release of pre-formed antibody.

Authors:  K J Turner; P G Holt; B J Holt; K J Cameron
Journal:  Clin Exp Immunol       Date:  1983-02       Impact factor: 4.330

4.  A morphological and functional study on antigen binding and endocytosis by immunocytes.

Authors:  B Goud; J C Antoine; N K Gonatas; A Stieber; S Avrameas
Journal:  Immunology       Date:  1980-12       Impact factor: 7.397

5.  Immunoglobulin isotype production by cycling human B lymphocytes in response to recombinant cytokines and anti-IgM.

Authors:  L Flores-Romo; M J Millsum; S Gillis; P Stubbs; C Sykes; J Gordon
Journal:  Immunology       Date:  1990-03       Impact factor: 7.397

6.  Regulation of antibody production by an antigen-specific EBV-transformed B-lymphoblastoid cell line: effect of high-dose antigen and antigen-pulsed T cells.

Authors:  G W McCaughan; M H Brown; R E Callard
Journal:  Immunology       Date:  1986-08       Impact factor: 7.397

7.  The assessment of anti-idiopathic antibodies as effective immunoregulatory probes in vivo.

Authors:  J C Olson; C R Wagner; G A Leslie
Journal:  Clin Exp Immunol       Date:  1982-05       Impact factor: 4.330

8.  Suppression of in vitro monoclonal human rheumatoid factor synthesis by antiidiotypic antibody. Target cells and molecular requirements.

Authors:  W J Koopman; R E Schrohenloher; J C Barton; E C Greenleaf
Journal:  J Clin Invest       Date:  1983-10       Impact factor: 14.808

9.  Regulation of resting and cycling human B lymphocytes via surface IgM and the accessory molecules interleukin-4, CD23 and CD40.

Authors:  J Gordon; M J Millsum; L Flores-Romo; S Gillis
Journal:  Immunology       Date:  1989-12       Impact factor: 7.397

10.  Mechanism of effector-cell blockade. I. Antigen-induced suppression of Ig synthesis in a hybridoma cell line, and correlation with cell-associated antigen.

Authors:  A W Boyd; J W Schrader
Journal:  J Exp Med       Date:  1980-06-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.